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Essay
G
lobal tuberculosis control 
is threatened by dramatic 
increases in HIV-related 
tuberculosis and by the emergence 
of multidrug-resistant strains. Highly 
lethal outbreaks of extensively drug-
resistant tuberculosis among HIV-
infected persons in South Africa 
[1] demonstrate the public health 
emergency that results when these two 
forces converge in the same setting. 
Fortunately, at this time of great need, 
tuberculosis drug development has 
been roused from its decades-long 
slumber. New ways of using existing 
drugs and the development of new 
drug classes hold great promise for 
the treatment of both drug-susceptible 
[2–6] and drug-resistant tuberculosis 
[4–8].
Children are a critical part of the 
global tuberculosis pandemic, with an 
estimated 900,000 cases and 100,000 
deaths per year [9]. In high-burden 
settings, children make up as much 
as 20% of incident cases of active 
tuberculosis [9,10]. Furthermore, 
young children have an increased risk 
of severe, rapidly progressive forms 
of tuberculosis, such as disseminated 
disease and meningitis (Figure 1) 
[11,12]. Therefore, it is imperative that 
children benefit from improvements 
made in tuberculosis treatment. 
However, children have only been 
included in one study of these new 
agents (a phase III trial of once-weekly 
rifapentine + isoniazid for latent 
tuberculosis) [13]. 
Barriers to Involving Children 
Although not well articulated in 
the published medical literature, a 
number of barriers to the involvement 
of children have been raised in 
discussions of tuberculosis drug 
development (Box 1). Our concern 
is that these barriers may, once again, 
lead the field down the path of least 
resistance—the exclusion of children 
from tuberculosis drug development 
efforts. 
What happens when children are not 
included in drug development. There 
is a rich history of clinical trials for 
tuberculosis treatment, beginning with 
the landmark streptomycin trial [14] 
and followed by a remarkable series 
of trials establishing that multidrug 
therapy could be curative, that it was 
possible to do so with ambulatory 
treatment, and that therapy could be 
shortened from two years to six months 
[15]. Children were almost completely 
left out of this series of clinical trials. 
The result? Nearly 40 years after the 
development of short-course treatment 
in adults, there are still fundamental 
uncertainties about age-appropriate 
dosing of isoniazid, rifampicin, 
pyrazinamide, and ethambutol [16,17]. 
Children, particularly very young 
children, do not achieve adequate 
serum concentrations of these agents 
when given weight-based dosing 
based on pharmacokinetic data 
from adults. The uncertainties about 
pediatric dosing reflect the lamentable 
paucity of pharmacokinetic data for 
first-line drugs in children. Another 
consequence of the lack of involvement 
of children in the initial phase of 
tuberculosis drug development is that 
only in recent years has there been 
a substantial effort to manufacture 
child-friendly formulations of first-
line tuberculosis drugs (crushable 
mini-pills, granules, oral suspensions). 
A number of controversies in the 
treatment of pediatric tuberculosis 
stem from the lack of clinical trials 
focused on child-specific questions 
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Box 1. Barriers to Including 
Children in Tuberculosis Drug 
Development
sÈ )NFREQUENTÈTRANSMISSIONÈOFÈTUBERCULOSISÈ
from children to others
sÈ $IFFICULTYÈOFÈCONFIRMINGÈACTIVEÈ
tuberculosis among children
sÈ %XISTENCEÈOFÈEFFECTIVEÈTHERAPYÈFORÈDRUG

susceptible tuberculosis 
sÈ #ONCERNSÈABOUTÈPEDIATRIC
SPECIFICÈSIDEÈ
effects
sÈ 5NCERTAINTIESÈABOUTÈTHEÈAPPROPRIATEÈ
time to involve children in drug 
development and the optimal trial 
designs for doing so
sÈ 2EGULATORYÈREQUIREMENTSÈENGENDEREDÈ
by the inclusion of children
sÈ #ONCERNSÈABOUTÈFURTHERÈSUBDIVIDINGÈ
the limited resources available for drug 
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(e.g., the optimal duration and 
dosing frequency of tuberculosis 
treatment, how to ensure safe use of 
ethambutol in children). There are 
even greater uncertainties about less 
common therapeutic questions (e.g., 
the treatment or prevention of drug-
resistant disease).
The history of tuberculosis drug 
development reflects the lack of 
involvement of children and the 
consequences of that omission. 
Concerted efforts are necessary to avoid 
repeating this unfortunate experience 
in this era of renewed interest in 
tuberculosis drug development.
The example of antiretroviral drug 
development. Antiretroviral drugs have 
been evaluated among children, age-
specific pharmacokinetic data obtained, 
and child-friendly formulations 
developed and marketed. Throughout 
this process, the evaluation of 
antiretroviral drugs for children has not 
lagged far behind their development 
and licensure for adults. As a result, 
age-appropriate regimens are available 
in a range of formulations for children, 
and the rates of HIV-related morbidity 
and mortality decreased in concert 
for children [18–20] and adults [21]. 
The keys to this success were advocacy 
[22], earmarked funding for pediatric 
research, focused clinical trial designs 
on questions whose answers could 
not be extrapolated from research 
in adults, and incentives for the 
pharmaceutical industry to include 
children in drug development.
Overcoming the Barriers to the 
Involvement of Children
The first and perhaps the most 
important step toward involving 
children in tuberculosis drug 
development is to clearly articulate 
the necessity of doing so. To shine a 
light on the path of least resistance 
is to show how clearly unacceptable 
it is; children have the same right to 
benefit from research as do adults. 
Researchers, regulatory agencies, 
advocates, and government agencies 
and private foundations that fund 
drug development must insist that 
the development pathways for all new 
agents/regimens include specific plans 
for when and how children will be 
involved. 
Once agreement has been reached 
on the necessity of including children 
in trials of new tuberculosis treatment 
regimens, the specific barriers to 
the involvement of children must 
be identified and then overcome 
(Table 1). The difficulty of culture 
confirmation of active tuberculosis 
among children is well known [17]. 
Because a positive culture is both an 
enrollment criterion and the primary 
endpoint of phase II and III clinical 
trials for tuberculosis treatment, 
some observers have concluded that 
tuberculosis treatment trials cannot be 
done among children. This limitation is 
quite real—because of it, pediatric trials 
are not the setting for the definitive 
evaluation of the efficacy of a new drug 
or treatment regimen. However, it does 
not mean that treatment trials cannot 
be done among children. 
Improved specimen collection 
techniques (e.g., induced sputum 
and string test) can provide 
culture confirmation in a higher 
percentage of pediatric patients than 
previously thought possible [23–26]. 
Furthermore, case definitions for 
culture-negative pediatric tuberculosis 
can be used in clinical trials, as criteria 
both for enrollment and for evaluating 
efficacy [27,28]. While imperfect, these 
case definitions can be applied by an 
events committee blinded to treatment 
assignment to ensure unbiased 
assessment of diagnosis and response to 
treatment. 
Although concerns about pediatric-
specific side effects have led some to 
argue against inclusion of children 
in clinical trials, these concerns fail 
to recognize that new drugs will be 
used off-label among children, in 
the absence of data on pediatric 
pharmacokinetics and tolerability, as 
soon as they are approved for adults. 
Children are indeed vulnerable 
participants in research because 
of their inability to provide fully 
informed consent. However, an 
overzealous attempt to protect some 
children from the possible harms of 
research perversely causes harm, by 
either denying access to treatment 
or through exposing children to the 
risks of inappropriate dosages of new 
medications. 
Effective therapy is available for 
drug-susceptible tuberculosis. However, 
the limitations of current first-line 
tuberculosis treatment should be 
recognized. Despite the appeal of 
our current nomenclature of “short-
course therapy,” a six-month treatment 
duration leads to worrisome numbers of 
patients who do not complete treatment 
in many programmatic situations 
[29–32]. The side effects of current 
regimens are appreciable as well: high 
rates of bothersome side effects, such 
as nausea and vomiting, and substantial 
rates of serious adverse events, such 
as hepatotoxicity [33]. In spite of the 
availability of effective therapy for 
drug-susceptible tuberculosis, new 
agents should still be evaluated among 
doi:10.1371/journal.pmed.0050176.g001 
Figure 1. Chest Radiograph of an Infant with Pulmonary Tuberculosis, Complicated by an 
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children; there is much room for 
improvement in “short-course therapy.” 
At what points in tuberculosis 
drug development should studies be 
undertaken in children? This crucial 
question requires discussion among 
investigators, the pharmaceutical 
industry, advocates, and regulatory 
officials. As a starting point for such 
discussions, we offer initial suggestions 
in Table 2. If children are to be 
involved at specific points in drug 
development, appropriate timelines are 
needed for initial work on formulations 
and pharmacokinetic studies among 
children. It is inappropriate to wait 
until the drug development plan 
for a new drug or regimen has been 
completed in adults before beginning 
its evaluation in children.
What kinds of trials should be 
undertaken among children? Not all 
phase III trials in adults need repeating 
in children; it is highly likely that 
children will respond well to a new 
regimen if given a drug formulation 
and dose that achieves pharmacokinetic 
parameters comparable to those among 
adults. Questions that are specific to 
children, or where answers from adults 
are unlikely to extrapolate to children, 
require separate evaluation. Key 
examples of studies that must be done 
among children are those assessing the 
pharmacokinetics and tolerability of 
new drugs [17].
It can be difficult to obtain blood 
specimens by venipuncture from 
very young and very ill children. 
This challenge should not preclude 
pharmacokinetic studies of new 
antituberculosis drugs among children; 
more efficient study designs and 
techniques for use of ultra-small 
quantities of blood can overcome 
this limitation. Sparse sampling 
schemes analyzed with Bayesian 
statistical methods that incorporate 
pharmacokinetic data from adults, 
in addition to knowledge about 
maturation of metabolic pathways 
in children, facilitate the design and 
implementation of pharmacokinetic 
studies in children [34]. 
Table 1. Summary of Barriers to the Involvement of Children in Tuberculosis Drug Development and Suggested Ways to  
Overcome Them
Barrier Ways In Which Barriers Can Be Overcome
The difficulty of diagnosing active tuberculosis in children Clinical trials of new drugs/regimens can proceed using validated case definitions for active 
disease, confirmed by blinded events review committees, even though many of the participants 
will not have culture-confirmed tuberculosis
Lack of pharmacokinetic data from children and the difficulty  
of performing pharmacokinetic sampling in young children
Validation of methods for doing pharmacokinetic studies using more easily obtained, very low-
volume samples
Identification of local sites that already have the capacity to perform such studies
Unwarranted complacency about the effectiveness of therapy  
for children with drug-susceptible tuberculosis
Initial evaluation of novel drug classes among children with proven or suspected drug-resistant 
tuberculosis
Ensure that pharmacokinetics and tolerability of new drugs for drug-susceptible tuberculosis 
are evaluated among children while their efficacy is being investigated among adults
Trial design issues (endpoints, appropriate sample sizes) Collaboration with pediatric trialists in the antiretroviral and cancer treatment fields
Concerns about pediatric-specific side effects Appropriate monitoring during clinical trials involving children
2ECOGNITIONÈTHATÈDRUGÈTOXICITYÈMAYÈBEÈLESSÈFREQUENTÈAMONGÈCHILDREN
Concern that involving children in tuberculosis drug development  
will complicate the research oversight and regulatory aspects of  
clinical trials 
)NVOLVEMENTÈOFÈCHILDRENÈINÈDRUGÈDEVELOPMENTÈISÈAÈREQUIREMENTÈOFÈSOMEÈFUNDINGÈAGENCIESÈEGÈ
US National Institutes of Health)
Provision of incentives by some regulatory authorities (e.g., US Food and Drug Administration 
and EU European Medicines Agency) to encourage the involvement of children in research in 
particular areas
Concerns about diffusing the very limited funds for tuberculosis  
drug development into too many areas (dividing an already small  
research pie into too many pieces)
Use of the involvement of children in tuberculosis drug development as a basis for more 
effective advocacy, and a way to increase overall funding for the field (“grow the pie”)
doi:10.1371/journal.pmed.0050176.t001
Table 2. Suggested Types of Research Activity among Children by the Stage of Clinical Trial Efforts among Adults for a New 
Antituberculosis Drug/Regimen
Clinical Trial Phase among Adults Suggested Research Activities among Children
I (Single and multiple-dose PK and tolerability among healthy adults) None
IIa (Early bactericidal activity and PK—patients with tuberculosis) Initial work on possible formulations for young children
IIb (Sputum culture conversion over the first 2–4 months of therapy) Initial PK studies among children with tuberculosis
III (Randomized trial with tuberculosis outcomes as the primary endpoint) Randomized comparison of the new drug/regimen with PK and tolerability as primary 
endpoints; efficacy as a secondary endpoint
Expanded access (compassionate use) protocol for children with known or suspected 
drug-resistant disease and poor treatment options
IV (Further evaluation of a regimen shown to be effective in an initial phase III trial) Additional studies among key subgroups of children—those <3 years old, those with 
central nervous system involvement
Validation of PK of formulations and doses chosen for clinical practice
PK, pharmacokinetics
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An instructive example of optimizing 
methodologies for pharmacokinetic 
studies for children comes from 
malaria research. Severe malaria is 
predominantly a disease of young 
children, so it is critical that the 
pharmacokinetics of antimalarial drugs 
among infants and young children be 
well understood. In these studies, very 
small samples of blood (100 microliters) 
obtained by finger- or heel-stick are 
blotted onto filter paper, allowed to 
dry, stored at room temperature, and 
later used to determine concentrations 
of antimalarial drugs [34,35]. Thus, 
pharmacokinetic studies can be 
extended to infants and young 
children, and such samples can be 
obtained under field conditions where 
the disease is common. The extension 
of these techniques to the study of 
new antituberculosis drugs requires 
further research, but the challenge 
of pharmacokinetic sampling among 
young children calls for this kind of 
innovation. 
There are many regulatory steps 
between the development of a study 
protocol and its implementation 
at study sites. Some have expressed 
concern that involving children in 
drug development will slow down 
the already lengthy timeline for 
study implementation by triggering 
more rigorous regulatory review. 
This concern may be well founded. 
However, key funding and regulatory 
agencies have policies and incentives 
to encourage evaluation of new drugs 
among children for conditions, like 
tuberculosis, that are common among 
that age group (the US National 
Institutes of Health requires specific 
justification if children are not included 
in a study). Some of those incentives, 
such as extended patent protection 
for the United States market, are 
unlikely to encourage tuberculosis 
drug development efforts for children. 
However, the US Food and Drug 
Administration has recently been 
authorized to take additional steps 
to promote the inclusion of children 
in drug development [36], and the 
European Union now requires that 
any new drug that could potentially 
be used in children have a Pediatric 
Implementation Plan for the drug to be 
licensed in adults [37]. Other groups 
are developing alternative incentive 
structures for diseases of poverty, such 
as tuberculosis [38].
Finally, there is the concern that 
including children in clinical trials will 
dilute the already inadequate funding 
for tuberculosis drug development 
[39], thus slowing down the pathway 
to licensure of new drugs. Proponents 
of this zero-sum argument may be 
willing to face difficult facts, but risk 
fostering the continued existence 
of an unacceptable situation. The 
expansion of antiretroviral therapy and 
the treatment of multidrug-resistant 
tuberculosis in high-burden settings 
are examples of two interventions 
which were said to be inadvisable, 
based on zero-sum arguments, but 
which have now been shown to be both 
feasible and critical for disease control 
[40–42]. Rather than being a detriment 
to funding for tuberculosis drug 
development, the inclusion of children 
may draw funding to the field.
Summary
We are on the threshold of 
revolutionary improvements in the 
treatment of tuberculosis. Within five 
to ten years, it is likely that highly 
effective three-month regimens will be 
available to treat both active and latent 
drug-susceptible tuberculosis. New 
drug classes that have the potential to 
dramatically improve the treatment 
of multidrug-resistant tuberculosis are 
entering clinical trials. Children have 
the same right as adults to benefit from 
research with these new treatments. By 
making a deliberate choice to avoid the 
path of least resistance, we can ensure 
that both adults and children benefit 
from these advances in tuberculosis 
treatment.  
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